- Home
- SKYE vs PSTL Comparison
SKYE vs PSTL Comparison
Compare SKYE & PSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYE | PSTL |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 329.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SKYE | PSTL |
|---|---|---|
| Price | $1.02 | $16.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $14.75 | ★ $17.58 |
| AVG Volume (30 Days) | ★ 528.9K | 218.2K |
| Earning Date | 11-10-2025 | 02-25-2026 |
| Dividend Yield | N/A | ★ 6.04% |
| EPS Growth | N/A | ★ 508.95 |
| EPS | N/A | ★ 0.48 |
| Revenue | N/A | ★ $91,195,000.00 |
| Revenue This Year | N/A | $25.13 |
| Revenue Next Year | N/A | $13.50 |
| P/E Ratio | ★ N/A | $33.24 |
| Revenue Growth | N/A | ★ 26.65 |
| 52 Week Low | $0.68 | $12.26 |
| 52 Week High | $5.75 | $16.50 |
Technical Indicators
Market Signals| Indicator | SKYE | PSTL |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 58.44 |
| Support Level | $0.68 | $15.77 |
| Resistance Level | $0.95 | $16.14 |
| Average True Range (ATR) | 0.12 | 0.30 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 67.03 | 61.54 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.